• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.


(CAS: )

Suppliers of D341-0349

Company Name Email Tel Country
AMEDCHEM [email protected] +862168061059 CHINA

Fax: Purity: Brand:

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of D341-0349

D341-0349 is a novel cyclin-dependent kinase 8 (CDK8) inhibitor. The inhibition rate is 50.8±2.6% at 10 μM. CDK8 gene expression correlates with increased mortality in colorectal, breast, and ovarian cancers and its overexpression is essential for the proliferation of cancer cells. Due to its key roles in oncogenesis, CDK8 has recently attracted considerable attention. Inhibitors of CDK8 offer a novel strategy for the treatment of various cancers.

Solubility of D341-0349

Solubility Sources

Storage Condition of D341-0349

Storage Condition Sources

MSDS Information

MSDS Sources

Quality Control and Spectral Data

QC Reports Sources

Mechanism and Indications

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Neurological Disease

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase

Chemical Information

M.Wt Formula CAS No. Synonyms
343.44 C21H17N3S

Structure Information of D341-0349

Smiles C12SC=C(C3C=CC=CC=3)C1=C(N1CC3C=CC=CC=3CC1)N=CN=2
InChI InChI=1S/C21H17N3S/c1-2-7-16(8-3-1)18-13-25-21-19(18)20(22-14-23-21)24-11-10-15-6-4-5-9-17(15)12-24/h1-9,13-14H,10-12H2

Related Products

Other Form Products of D341-0349

Name CAS Formula Suppliers

Recommended Products in Same Target

Name CAS Formula Suppliers
LY2857785 1619903-54-6 C26H36N6O 12
THZ2 1604810-84-5 C31H28ClN7O2 10
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 22
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 5
ML167 1285702-20-6 C19H17N3O3 15
AMG 925 1401033-86-0 C26H29N7O2 15
LDC000067 1073485-20-7 C18H18N4O3S 11
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 8
LEE011 (succinate) 1374639-75-4 C27H36N8O5 9
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 8
LEE011 1211441-98-3 C23H30N8O 21
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 6
Wogonin 632-85-9 C16H12O5 28
1-NM-PP1 221244-14-0 C20H21N5 17
WHI-P180 211555-08-7 C16H15N3O3 13
THZ1 1604810-83-4 C31H28ClN7O2 18
Senexin A 1366002-50-7 C17H14N4 8
CDK4-IN-1 1256963-02-6 C22H29ClN8 9
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 16
Purvalanol B 212844-54-7 C20H25ClN6O3 22

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:


[1].He LJ, et al. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes. Bioorg Med Chem Lett. 2019 Feb 15;29(4):549-555.
With the aim of discovering novel cyclin-dependent kinase 8 (CDK8) inhibitors, a combined similarity search and molecular docking approach was employed, which led to 32 hits. Biological tests led to the discovery of several novel submicromolar inhibitors. In particular, compound C768-0769 (ZC0201) showed good CDK8 inhibitory activity, and compound ZC0201 effectively suppressed HCT-116 colorectal cancer cell proliferation by inducing G1/S transition arrest. Furthermore, modulation of phosphorylated signal transducer and activator of transcription 1 (Ser 727) (STAT1SER727), a pharmacodynamic biomarker of CDK8 activity, demonstrated that ZC0201 may cause G1/S transition arrest through CDK8 activity inhibition. Due to its good cellular activity, ZC0201 may be an ideal lead compound for further modification as a potential cancer therapeutic agent.

Tags: buy D341-0349 | D341-0349 IC50 | D341-0349 price | D341-0349 cost | D341-0349 solubility | D341-0349 purchase | D341-0349 manufacturer | D341-0349 research buy | D341-0349 order | D341-0349 MSDS | D341-0349 chemical structure | D341-0349 Storage condition | D341-0349 molecular weight | D341-0349 mw | D341-0349 datasheet | D341-0349 supplier | D341-0349 cell line | D341-0349 NMR | D341-0349 MS | D341-0349 IR | D341-0349 solubility | D341-0349 Safe information | D341-0349 Qc and Spectral Information | D341-0349 Clinical Information | D341-0349 Clinical Trial | D341-0349 Route of Synthesis | D341-0349 storage condition | D341-0349 diseases and conditions | D341-0349 flash point | D341-0349 boiling point | D341-0349 melting point | D341-0349 storage condition | D341-0349 brand